ClinicalTrials.gg
TerminatedNCT00266812Updated Jun 8, 2017Results posted

Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

A Phase 2 interventional study of Temozolomide and radiotherapy and Whole brain radiotherapy in Carcinoma, Non-Small-Cell Lung, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Patient target could not be reached within the planned timeframe.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Mar 2005, registered Dec 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung — none open to participants now, none under way, none of them phase 3. Temozolomide · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 16
35 · median 56
Started
2005
with 3 others
Phase 2
12 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
6 of 16
Merck Sharp & Dohme LLC

Among the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 4 that started in 2005, is one of 12 in phase 2, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing temozolomide in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This is a phase II, randomized, multicenter, open-label study designed to assess the safety and tolerability of concomitant chemotherapy with low-dose temozolomide during whole brain radiation and later on at 14 days on/14 days off schedule in patients with cerebral metastases from non-small cell lung cancer (NSCLC). The response to temozolomide will be evaluated by clinical follow up and Magnetic Resonance Imaging (MRI) performed every 2 months. Progression-free survival at 6 months, duration of overall survival, and quality of life will also be evaluated.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • temozolomide
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior histologic confirmation of non-small cell lung cancer (NSCLC).
  • Optional: NSCLC histologic confirmation of of NSCLC.
  • Presence of unidimensionally in the brain.
  • No previous or current at other sites with the exception of adequately treated in situ carcinoma of the cervix or basal and squamous carcinoma of the skin.
  • Age: >18 years.
  • Subjects must not have systemic disease that in the opinion of the investigator is in immediate need of chemotherapy
  • Performance status >=70%.
  • (ANC) >1,500/mm\^3, >100,000/mm\^3, >8 g/dL.
  • Serum creatinine and \<1.5 times upper normal limit of testing laboratory.
  • Serum glutamic oxaloacetic transaminase (), serum glutamic pyruvic transaminase (SGPT) \<3 times upper limit of testing laboratory.
  • Palliative radiation therapy to thorax and bone or other organs (except brain) is acceptable.
  • Prior neurosurgery >2 weeks from initiating treatment with temozolomide.
  • Cortisone medication stable or decreasing within 2 weeks prior to initiating treatment with temozolomide.
  • Patient is not pregnant or nursing and is advised and willing to use an effective method of .
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy or biologic therapy within four weeks prior to initiating therapy with temozolomide.
  • Prior radiation therapy for brain \<4 weeks from initiating therapy with temozolomide.
  • Surgery within two weeks prior to temozolomide administration.
  • Recursive Partitioning Analysis (RPA) class III
  • Patients with a single amenable to radiosurgery of resection
  • Known (HIV) disease.
  • Acute infection requiring intravenous antibiotics.
  • Any reason making compliance to the protocol improbable.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Chemotherapy with temozolomide and radiotherapy

    Drug: Temozolomide and radiotherapy

  • Active comparator
    Radiotherapy alone

    Procedure: Whole brain radiotherapy

Interventions

  • DrugTemozolomide and radiotherapy

    Drug page: Temozolomide

    Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).

    Also known as: Temodal, TMZ, SCH 052365

  • ProcedureWhole brain radiotherapy

    2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progression-free Survival (6 Month)

    The occurrence of progression will be compared between the study groups by Kaplan-Meier curves. Responsiveness to temozolomide will be evaluated by brain Magnetic Resonance Imanging (MRI)/Computed Tomography (CT), thorax CT, and Quality of Life (QoL) assessments. Progression-free is defined as \<25% increase in tumor size on CT or MRI.

    Time frame: 6 months

07

Results

Posted Sep 4, 2009

Participant flow

Participant flow — Overall Study
MilestoneChemotherapy With Temozolomide and RadiotherapyRadiotherapy Alone
Started2213
Completed12
Not completed2111
Withdrew: Disease progression93
Withdrew: Death54
Withdrew: Adverse event31
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject02
Withdrew: Discontinued before starting study drug40

Outcome measures

PrimaryNumber of Participants With Progression-free Survival (6 Month)

The occurrence of progression will be compared between the study groups by Kaplan-Meier curves. Responsiveness to temozolomide will be evaluated by brain Magnetic Resonance Imanging (MRI)/Computed Tomography (CT), thorax CT, and Quality of Life (QoL) assessments. Progression-free is defined as \<25% increase in tumor size on CT or MRI.

Time frame:
6 months
Reported as:
Number · Participants
Number of Participants With Progression-free Survival (6 Month)
ParticipantsChemotherapy With Temozolomide and RadiotherapyRadiotherapy Alone
Number of Participants With Progression-free Survival (6 Month)88

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemotherapy With Temozolomide and Radiotherapy—8/18 (44.4%)15/18 (83.3%)
Radiotherapy Alone—4/13 (30.8%)8/13 (61.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventChemotherapy With Temozolomide and RadiotherapyRadiotherapy Alone
DEATHGeneral disorders2/181/13
DIARRHOEAGastrointestinal disorders0/181/13
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/181/13
HOSPITALISATIONSurgical and medical procedures1/181/13
NAUSEAGastrointestinal disorders1/180/13
VOMITINGGastrointestinal disorders1/180/13
ASTHENIAGeneral disorders1/180/13
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders1/180/13
PNEUMONIAInfections and infestations1/180/13
BACK PAINMusculoskeletal and connective tissue disorders1/180/13
Most frequent other events
Showing 10 of 51
Most frequent other events
EventChemotherapy With Temozolomide and RadiotherapyRadiotherapy Alone
DEPRESSED MOODPsychiatric disorders4/181/13
NAUSEAGastrointestinal disorders3/180/13
VOMITINGGastrointestinal disorders3/180/13
DYSPNOEARespiratory, thoracic and mediastinal disorders3/181/13
DEPRESSIONPsychiatric disorders0/182/13
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders2/180/13
MOTOR DYSFUNCTIONNervous system disorders2/180/13
SLEEP DISORDERPsychiatric disorders2/181/13
VERTIGOEar and labyrinth disorders0/181/13
DEATHGeneral disorders1/181/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Chemotherapy With Temozolomide and RadiotherapyRadiotherapy AloneTotal
Mean65.12 ± 12.7263.02 ± 8.7664.3 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Chemotherapy With Temozolomide and RadiotherapyRadiotherapy AloneTotal
Female9514
Male13821
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2005 to primary completion in Jan 2008, 34 months.

Results were first posted in Sep 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2005
First posted
Dec 19, 2005
StartActual
Mar 8, 2005
Primary completionActual
Jan 16, 2008
CompletionActual
Jan 16, 2008
Results first posted
Sep 4, 2009
Last update
Jun 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00266812
Collaborators
AESCA Pharma GmbH
Responsible party
Sponsor
First posted
Dec 19, 2005
Start date
Mar 8, 2005
Primary completion
Jan 16, 2008
Completion
Jan 16, 2008
Results posted
Sep 4, 2009
Last update
Jun 8, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion